Overview

Assess the Safety and Efficacy of Nephoxil® in Subjects With End Stage Renal Disease (ESRD) on Dialysis

Status:
Completed
Trial end date:
2019-05-31
Target enrollment:
Participant gender:
Summary
To assess the long-term safety and effectiveness of Nephoxil® for the treatment of hyperphosphatemia in patients with ESRD undergoing dialysis.
Phase:
Phase 4
Details
Lead Sponsor:
Panion & BF Biotech Inc.
Treatments:
Chelating Agents
Citric Acid
Ferric Compounds